期刊文献+

Diagnosis and surgical treatment of hepatic hilar cholangiocarcinoma 被引量:3

Diagnosis and surgical treatment of hepatic hilar cholangiocarcinoma
在线阅读 下载PDF
导出
摘要 BACKGROUND: Hepatic hilar cholangiocarcinoma can be diagnosed early with the progress in diagnostic imaging, and thus the rate of resection of the tumor has increased markedly. To assess the effectiveness of resection, we reviewed 185 cases of hepatic hilar cholangiocarcinoma diagnosed and treated at our hospital. METHODS: The clinical data of 185 patients with hepatic hilar cholangiocarcinoma who had been treated surgically from 1972 to 2006 were retrospectively analyzed. RESULTS: The records of the 185 patients were divided into first stage (1972-1986) or second stage (1987-2006) according to the incidence of the tumor and its resection rate. Primary symptoms included upper abdominal discomfort or pain, anorexia, tiredness, weight loss and progressive jaundice. Ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), and magnetic resonance cholangiopancreatography (MRCP) were first line methods for atraumatic diagnosis. If the patients displayed intrahepatic bile duct dilatation or were diagnosed as suffering from extrahepatic obstructive jaundice, percutaneous transhepatic cholangiography (PTC), MRCP or endoscopic retrograde cholangiopancreatography (ERCP) should be used. In this series, 87 patients underwent resection of the tumor (47.0%). Of the 87 patients, 43 received radical resection and 44 palliative resection. Fifteen patients underwent resection in the first stage and 72 in the second stage. A total of 74 patients were followed up after the resection. The median survival time of the radical resection group was 37 months and that of the palliative resection group was 17 months (P<0.001). The other 62 patients receiving no resection died within 1.5 years. CONCLUSIONS: Once patients are diagnosed with hepatic hilar cholangiocarcinoma, they should undergo exploratory laparotomy. Resection is the most effective method for the treatment of hepatic hilar cholangiocarcinoma. BACKGROUND: Hepatic hilar cholangiocarcinoma can be diagnosed early with the progress in diagnostic imaging, and thus the rate of resection of the tumor has increased markedly. To assess the effectiveness of resection, we reviewed 185 cases of hepatic hilar cholangiocarcinoma diagnosed and treated at our hospital. METHODS: The clinical data of 185 patients with hepatic hilar cholangiocarcinoma who had been treated surgically from 1972 to 2006 were retrospectively analyzed. RESULTS: The records of the 185 patients were divided into first stage (1972-1986) or second stage (1987-2006) according to the incidence of the tumor and its resection rate. Primary symptoms included upper abdominal discomfort or pain, anorexia, tiredness, weight loss and progressive jaundice. Ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), and magnetic resonance cholangiopancreatography (MRCP) were first line methods for atraumatic diagnosis. If the patients displayed intrahepatic bile duct dilatation or were diagnosed as suffering from extrahepatic obstructive jaundice, percutaneous transhepatic cholangiography (PTC), MRCP or endoscopic retrograde cholangiopancreatography (ERCP) should be used. In this series, 87 patients underwent resection of the tumor (47.0%). Of the 87 patients, 43 received radical resection and 44 palliative resection. Fifteen patients underwent resection in the first stage and 72 in the second stage. A total of 74 patients were followed up after the resection. The median survival time of the radical resection group was 37 months and that of the palliative resection group was 17 months (P<0.001). The other 62 patients receiving no resection died within 1.5 years. CONCLUSIONS: Once patients are diagnosed with hepatic hilar cholangiocarcinoma, they should undergo exploratory laparotomy. Resection is the most effective method for the treatment of hepatic hilar cholangiocarcinoma.
机构地区 Harbin Med Coll
出处 《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS 2007年第6期631-635,共5页 国际肝胆胰疾病杂志(英文版)
关键词 bile duct neoplasms hepatic hilar cholangiocarcinoma DIAGNOSIS surgical treatment bile duct neoplasms hepatic hilar cholangiocarcinoma diagnosis surgical treatment
  • 相关文献

参考文献5

二级参考文献14

  • 1田雨霖,中国实用外科杂志,1998年,18卷,365页
  • 2周宁新,中华外科杂志,1997年,35卷,649页
  • 3Ozkan H,Kaya M,Cengiz A.Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.Hepatogastroenterology,2003,50:1669-1674.
  • 4Chen CY,Shiesh SC,Tsao HC,et al.The assessment of biliary CA 125,CA 19-9 and CEA in diagnosing cholangiocarcinoma--the influence of sampling time and hepatolithiasis.Hepatogastroenterology,2002,49:616-620.
  • 5Ramage JK,Donaghy A,Farrant JM,et al.Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis.Gastroenterology,1995,108:865-869.
  • 6Uenishi T,Kubo S,Hirohashi K,et al.Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer.Br J Cancer,2003,88:1894-1899.
  • 7Tangkijvanich P,Thong-ngam D,Theamboonlers A,et al.Diagnostic role of serum interleukin 6 and CA 19-9 in patients with cholangiocarcinoma.Hepatogastroenterology,2004,51:15-19.
  • 8Torzilli G,Makuuchi M,Ferrero A,et al.Accuracy of the preoperative determination of tumor markers in the differentiation of liver mass lesions in surgical patients.Hepatogastroenterology,2002,49:740-745.
  • 9周宁新,黄志强,冯玉泉,顾万清,蔡守旺,张文智,黄晓强,段云鹏,王敬,纪文斌.肝门部胆管癌103例外科治疗远期疗效的评析[J].中华外科杂志,1997,35(11):649-653. 被引量:110
  • 10朱理玮.原发性胆管癌分子生物学研究现状[J].中国实用外科杂志,1998,18(6):327-328. 被引量:3

共引文献69

同被引文献16

引证文献3

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部